The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019.
Atopic dermatitis
Burden
GBD 2019
Prevalence
Years lived with disability
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
17
03
2021
revised:
15
10
2021
accepted:
15
10
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a chronic disease with growing prevalence and has become a global public health problem. However, little is known about the burden caused by AD in China. To access the prevalence and burden of AD in China. We estimated the prevalence and year lived with disability (YLD) of AD in China, by different age and sex groups. We also compared the burden of AD in China with other countries in the Group of Twenty (G20). We analyzed the changes in the number of AD patients and their YLDs by cause decomposition from 1990 to 2019. AD was the twenty-fourth leading cause of the burden of 369 diseases in China in 2019. From 1990 to 2019, the age-standardized prevalence and YLD rate of AD in China increased by 1.04% and 1.43% respectively, which were the second and the largest increase among the G20 and both higher than the global average (-4.29% and -4.14%). The number of patients with AD increased by 25.65%, of which 20.16% was due to population growth, 3.85% due to population aging, and 1.64% due to age-specific prevalence. Both the prevalence and YLD rate of AD were higher in 1 to 4 year-olds and 95+ years age group. Before the age of 10, the prevalence and YLD rate of AD in males were higher than those in females, while there was a marked sex shift at the ages of 10 to 14. AD is a serious public health problem in China. Substantial variations exist in burden due to AD between male and female, and in age groups. Considering these findings will be important for developing preventive strategies and treatments to reduce the burden of AD.
Sections du résumé
BACKGROUND
BACKGROUND
Atopic dermatitis (AD) is a chronic disease with growing prevalence and has become a global public health problem. However, little is known about the burden caused by AD in China.
OBJECTIVE
OBJECTIVE
To access the prevalence and burden of AD in China.
METHODS
METHODS
We estimated the prevalence and year lived with disability (YLD) of AD in China, by different age and sex groups. We also compared the burden of AD in China with other countries in the Group of Twenty (G20). We analyzed the changes in the number of AD patients and their YLDs by cause decomposition from 1990 to 2019.
RESULTS
RESULTS
AD was the twenty-fourth leading cause of the burden of 369 diseases in China in 2019. From 1990 to 2019, the age-standardized prevalence and YLD rate of AD in China increased by 1.04% and 1.43% respectively, which were the second and the largest increase among the G20 and both higher than the global average (-4.29% and -4.14%). The number of patients with AD increased by 25.65%, of which 20.16% was due to population growth, 3.85% due to population aging, and 1.64% due to age-specific prevalence. Both the prevalence and YLD rate of AD were higher in 1 to 4 year-olds and 95+ years age group. Before the age of 10, the prevalence and YLD rate of AD in males were higher than those in females, while there was a marked sex shift at the ages of 10 to 14.
CONCLUSION
CONCLUSIONS
AD is a serious public health problem in China. Substantial variations exist in burden due to AD between male and female, and in age groups. Considering these findings will be important for developing preventive strategies and treatments to reduce the burden of AD.
Identifiants
pubmed: 34820052
doi: 10.1016/j.waojou.2021.100604
pii: S1939-4551(21)00098-3
pmc: PMC8591460
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100604Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Allergol Immunopathol (Madr). 2015 May-Jun;43(3):238-42
pubmed: 25087092
J Allergy Clin Immunol. 2016 Jul;138(1):310-312.e3
pubmed: 26971689
J Allergy Clin Immunol. 2019 Jan;143(1):1-11
pubmed: 30612663
Biomed Res Int. 2016;2016:2568301
pubmed: 27957490
Ann Allergy Asthma Immunol. 2020 Dec;125(6):665-673.e1
pubmed: 32971247
BMJ Open Respir Res. 2019 Sep 13;6(1):e000460
pubmed: 31673365
Medicine (Baltimore). 2017 Mar;96(11):e6317
pubmed: 28296746
Int J Mol Sci. 2019 Sep 20;20(19):
pubmed: 31547021
J Pediatr. 2020 Jun;221:138-144.e3
pubmed: 32171558
J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S118-27
pubmed: 14657842
JAMA Dermatol. 2017 May 1;153(5):406-412
pubmed: 28249066
J Allergy Clin Immunol Pract. 2020 Jan;8(1):91-101
pubmed: 31474543
J Allergy Clin Immunol. 2014 Oct;134(4):769-79
pubmed: 25282559
Int J Environ Res Public Health. 2016 May 27;13(6):
pubmed: 27240388
J Allergy Clin Immunol. 2019 Jul;144(1):144-156
pubmed: 30685456
J Dermatol. 2019 Oct;46(10):825-834
pubmed: 31436343
Clin Rev Allergy Immunol. 2019 Jun;56(3):322-332
pubmed: 29306980
Ann Nutr Metab. 2015;66 Suppl 1:8-16
pubmed: 25925336
Front Immunol. 2018 Dec 18;9:2997
pubmed: 30619350
Nutrients. 2015 Nov 13;7(11):9440-52
pubmed: 26580648
Toxicol Res. 2015 Jun;31(2):89-96
pubmed: 26191377
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Clin Exp Allergy. 1998 Sep;28(9):1089-99
pubmed: 9761012
Contact Dermatitis. 2020 Jan;82(1):10-17
pubmed: 31461531
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Feb 6;51(2):132-136
pubmed: 28219151
Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Apr;49(4):289-91
pubmed: 26081527
J Allergy Clin Immunol. 2015 Mar;135(3):721-8.e6
pubmed: 25579484
Environ Health. 2018 Jan 17;17(1):8
pubmed: 29343261